The success of any company is through its management and leadership. MDI has a team of dedicated and experienced management specialists who seek new business opportunities and operate an efficient and profitable company. The company is overseen by its Board of Directors who offer an extensive knowledge base across business, finance and the health industry, who together, make the necessary decisions for the welfare of MDI’s shareholders and the growth of the company.
Chief Executive Officer
Chief Financial Officer/Company Secretary
Director of Scientific Affairs
Head of Medical Affairs
Chi Wai Ng
Head of Regulatory Affairs
Head of quality
Director of Research & Operations
General Manager – Sales and Marketing
Board of Directors
Mr. David Williams, B.Ec (Hons), M.Ec, FAICD
David is Managing Director of Kidder Williams Ltd, with over 30 years experience in the investment banking sector. He is also Chairman of PolyNovo Ltd.
Mr. Allan McCallum, Dip.Ag.Science, MAICD
Allan has over 20 years of public company experience including an ASX 50 company and has served on numerous committees. Allan is Chairman of Tassal Group Limited and Cann Group Limited.
Dr. Harry Oxer, AM, ASM, KStJ, MA (Hons), MB.BChir (Cantab), MRCS.LRCP, DA, FFARCS, FRCA, FFARACS, FANZCA, FACAP, DipDHM
Harry is a Medical Consultant to St John Ambulance in Western Australia. Harry is a member of the State Executive for St John Ambulance (WA), and was the previous Medical Director for twenty-six years.
He has taught, lectured and published extensively over the years, both nationally and internationally. Harry is also a past Chairman of the Australian Resuscitation Council and has a major interest in resuscitation, oxygen therapy, and pain relief.
Mr. Max Johnston
Max was appointed a Director of the company with effect from November 2012. Max is also non-executive director of PolyNovo Limited and a former non-executive director of Enero Group Limited.
For 11 years he was President and Chief Executive Officer of Johnson & Johnson Pacific and an Executive Director of Johnson & Johnson.
Max has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of ASMI. Max has had extensive overseas experience during his career in leading businesses in both Western and Central-Eastern Europe, Africa as well as Asia- Pacific.
Mr Hoare is the Managing Director of Lohmann & Rauscher (Australia and New Zealand), a private EU based medical device company. Previously, he was Managing Director of Smith & Nephew (Aus/NZ). which is one of the company’s largest global subsidiaries outside of the USA. Until 2014 he served as President of Smith & Nephew’s Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in Marketing, Divisional and General Management. Mr Hoare’s career also included a senior role at Bristol-Myers Squibb in surgical products, and Vice-Chair of Australia’s peak medical device body, Medical Technology Association of Australia. Leon is also a Non-executive Director of PolyNovo Limited (ASX: PNV).
Leon’s 30 years of healthcare industry experience, spanning multiple medical technologies, and management of all aspects of a major market-leading medical device company, coupled with extensive experience in Asia, will add depth to the Board of Directors.
Philip, a Chartered Accountant, has an extensive finance background and commenced working in investment banking in 1996 at Hambros Corporate Finance following ten years industry experience in senior finance roles with ASX listed public company OAMPS Limited. Prior to these roles, Philip worked for ten years within the Assurance Division at Arthur Andersen & Co.
From January 2006 to July 2013 Philip was an Executive Director at Corporate Finance Advisory firm Kidder Williams. Philip is also a Director of PolyNovo Limited (ASX:PNV).
Philip is also Chairman of the MDI Audit and Risk Committee.